Volume 12, Issue 4 (11-2022)                   JABS 2022, 12(4): 422-430 | Back to browse issues page


XML Persian Abstract Print


1- Department of Genetic, Marvdasht Branch, Islamic Azad University, Marvdasht, Iran
2- Department of Medical Genetic, National Institute for Genetic Engineering and Biotechnology, Tehran, Iran , housh62@yahoo.com
3- Department of Biology, Marvdasht Branch, Islamic Azad University, Marvdasht, Iran
Abstract:   (734 Views)
Background & Objective: Breast cancer consists of a heterogeneous group of tumours with different prognosis and is the most common cause of cancer-related mortality among women. In this study, our goal was to evaluate the association of AURKA rs2273535 and CDKN1B rs34330 polymorphisms with risk of female breast cancer in southwest part of Iran.
Materials & Methods: This case-control study was done on 50 women with breast cancer and 50 healthy women without any symptoms or family history of breast cancer as the case and control group, respectively. Restriction fragment length polymorphism (RFLP- PCR) technique was designed to determine the AURKA rs2273535 and CDKN1B rs34330 gene polymorphisms. Afterwards, statistical analysis was done by means of SPSS (version 17).
Results: In current research, our finding showed that rs2273535 T allele increased the susceptibility of breast cancer (OR:2.58, 95%CI:1.5-31.09, P=0.006). Moreover, T allele in dominant phase could raise the risk of the breast cancer (OR:3.01, 65%CI:1.31-6.92, P=0.009). However, the other polymorphism, CDKN1B rs34330, revealed no associations with increased risk of breast cancer.
Conclusion: These findings suggest that AURKA rs2273535 may influence individual’s susceptibility to breast cancer. But we found no associations regarding CDKN1B rs34330 polymorphism and this type of cancer.
 
Full-Text [PDF 315 kb]   (678 Downloads)    
Type of Study: Research | Subject: Genetics
Received: 2022/07/2 | Accepted: 2022/10/15 | Published: 2022/12/28

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.